Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.57 |
| ▸ | RARB | P10826 | 11/20 | 0.57 |
| ▸ | RARG | P13631 | 10/20 | 0.57 |
| ▸ | RARA | P10276 | 6/20 | 0.57 |
| ▸ | RXRB | P28702 | 8/20 | 0.41 |
| ▸ | RXRG | P48443 | 8/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862497 | 1.00 | RXRA (0.57) | RXRARARBRARGRARARXRB | |
| SCHEMBL6757743 | 0.86 | RXRA (0.43) | RXRARARBRARGRARAPTGS1 | |
| SCHEMBL6757737 | 0.86 | RXRA (0.43) | RXRARARBRARGRARAPTGS1 | |
| SCHEMBL15886820 | 0.82 | RXRA (0.78) | RXRARARBRARGRARARXRB | |
| SCHEMBL8364736 | 0.82 | RXRA (0.78) | RXRARARBRARGRARARXRB | |
| SCHEMBL4895819 | 0.82 | RXRA (0.78) | RXRARARBRARGRARARXRB | |
| SCHEMBL4905159 | 0.82 | RXRA (0.78) | RXRARARBRARGRARARXRB | |
| SCHEMBL8366242 | 0.82 | RXRA (0.78) | RXRARARBRARGRARARXRB | |
| SCHEMBL727074 | 0.82 | RXRA (0.78) | RXRARARBRARGRARARXRB | |
| SCHEMBL727073 | 0.82 | RXRA (0.78) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720423-B2 | SKIN RELATED DISEASES; PROMOTE THE EXPRESSION OF OR BIND TO RECEPTORS BELONGING TO THE STEROID OR THYROID RECEPTOR SUPERFAMILY. | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | RXRB, RXRA, RXRG | RXRA 2/4885RARB 4/4885RARG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.